Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have uncovered biological differences ...

Patients share their unexpected journeys with multiple myeloma, revealing challenges and resilience in the face of a cancer ...

At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections.

This panel of multiple myeloma care partners shares diverse diagnostic journeys, offering vital insights for patients and ...

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...